肺吸入制剂的药代动力学评价手段研究进展  

Research progress of pharmacokinetic evaluation methods on inhalable formulations

作　　者：孔颖 李宁 卢杨 赵娣 任畅 邢晗 陈西敬 KONG Ying;LI Ning;LU Yang;ZHAO Di;REN Chang;XING Han;CHEN Xijing(Clinical Pharmacokinetics Laboratory,School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 211198,Jiangsu,China)

机构地区：[1]中国药科大学基础医学与临床药学学院临床药物代谢动力学研究室

出　　处：《中国临床药理学与治疗学》2019年第5期595-600,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金资助项目(81473272)

摘　　要：近年来,肺吸入制剂因其在局部治疗及全身治疗中的优越性而受到研究者的广泛关注。完善的评价体系关乎着肺吸入制剂的质量,但目前肺吸入制剂的评价仍侧重于制剂理化性质的鉴定,对药物代谢动力学评价涉及较少,且现有药动学评价手段和方式各异,评价体系尚不完善。本文综述近年来肺吸入制剂的药代动力学评价手段,包括动物药代动力学、酶代谢动力学及细胞药代动力学,以期为后续肺吸入制剂开发过程中的药代动力学评价体系的建设与完善提供思路。Inhalable formulations have attracted increasing attentions due to the superiority in both local and systemic therapy.Thorough evaluation system is related to the quality of formulations,but the reported papers concerning inhalable formulations mainly focused on the evaluation of physicochemical properties.Pharmacokinetic evaluation is relatively ignored and the evaluation system is unsound.This paper reviews the pharmacokinetic evaluation methods in recent years,including the pharmacokinetic studies in animals,enzymes and cells,to further provide information for the establishment and improvement of pharmacokinetic evaluation system.

关 键 词：肺部给药系统 吸入制剂 药代动力学评价 

分 类 号：R969.1[医药卫生—药理学]